Israels Biotechnology Industry

1
Israels Biotechnology Industry
Ambasciata dIsraele www.roma.mfa.gov.il BIONOVA
PadovaFiere 20 Aprile 2005
When Science Meets Passion
2
Outline of presentation
1
Israel A High-Tech Economy
Israeli Biotech Characteristics and Figures
2
3
Key Segments
4
Incentives
5
Conclusions
3
ISRAEL Facts Figures
Declared independence 1948 Area 22,300 sq
km Government parliamentary democracy Population
6,862,000 Population growth 1.8 Literacy
95.4 Economy advanced industrialized
market economy
4
ISRAEL - high income industrialized democracy
Per capita GDP - selected OECD members (2003,
current prices, US dollars)

Source IMF
5
ISRAEL Emphasis on Education and Research
Development
of population age 25-64 with 12 years of
education (1999)
Engineers per 10,000 employees (2002)
Expenditure on educationas of GDP (2000)
Civilian RD expenditure as of GDP (2001)
Source OECD Education at a Glance.2004
Source OECD and Central Bureau of Statistics
6
ISRAEL high-tech economy
Global technology firms invested in Israel
Israeli tech companies

7
Major Healthcare Corporations Invest in Israeli
Technology
8
ISRAELS BioTech Characteristicsand Figures
9
Israels BioTech Characteristics

• Skilled Brainpower.
• A strong Scientific Technological Base.
• Government Incentives.
• Well established companies like Interfarm
  (Ares-Serono), Biotechnology General.
• Ethical drugs in various development stages.
  (Copaxone with app. 500M sales, Rasagiline -
  FDA submission, several in phase II and III etc)

10
Where Academy Meets Industry
11
Advanced Research Patents

• Highest number of scientific publications per
  capita in the world
• 60 of publications are in biology and related
  fields
• First place in the world for granted patents per
  capita in the medical device area

12
Nobel Prizes
The Nobel Prize in Chemistry 2004 for the
discovery of ubiquitin-mediated protein
degradation  Aaron Ciechanover Technion Israel
Institute of Technology Haifa, Israel
Avram Hershko
Technion Israel Institute of Technology Haifa,
Israel Irwin RoseCollege of Medicine,
University of California, Irvine, USA
13
Government Support

• Biotechnology is one of the two nationally
  preferred industries
• Technology incubator program supports young
  companies
• National commitment to investment in RD funds

14
International Cooperation

• Binational research funds with many countries
  including Italy
• Full fledge membership of EU FP6
• Free trade agreements with the United States of
  America and the European Union
• Preferred national status in Australia, Canada,
  Japan and China

15
Annual Sales (in Million )
16
Number of Companies
In 2003 There were 466 companies in the Life
Sciences sector of which 149 were Biotech
17
Companies at Developmental Stage
Source ILSI Database - 2004
18
Israels Life Sciences Industry - Sectors
Source ILSI Database - 2004
19
Key Segments
20
Biotherapeutics

• Israels leading biotech sector, with 36
  companies generating 67 of biotech sales
• RD benefits from the countrys highly-advanced
  medical research
• Companies focus on
• Cell and Gene Therapy
• Drug Targeting
• Immunization
• Chemical Treatment

21
Platforms for Drug Research

• Highly-advanced medical research
• Market orientation and initiative spirit
• Excellent infrastructure and financial
  support for RD

Result in
22
Platforms for Drug Research

• Constant scientific advances in
• Drug Discovery
• Data Modeling
• Proteomics Infrastructure
• Proteomics and Glycomics
• Pharmacological Tools

23
Diagnostics

• The Israeli diagnostics industry ranks among the
  leading Western countries
• Prominence is based on technological excellence
  and innovation
• Companies stand in the forefront of RD and
  manufacturing of
• Imaging
• Diagnosis

24
Agro-biotech and Food

• Israels leadership of the field is based on
  advanced chemical and biological research
• The sector generates 23 of annual biotech sales
• Main activities
• Chemical Engineering
• Diagnosis
• Genetic Engineering
• Biological Warfare

25
Incentives
26
Office of Chief Scientist (OCS) support programs

• RD industrial fund (app. 300M)
• Incubators (app. 30M)
• Special support for Generic technologies and
  Academia Industry technology
• transfer (app. 60M)
• Seed Fund (app. 10M)
• International cooperation activities

27
OCS Grants by Technological sectors 2000, 2001,
2002
Total Life Sciences18

28
OCS Grants Forecast2007
29
Technological Incubators
Numbers of Bio-Tech projects 1999-2004

• Grants are 85 of the approved expenses, up to
  350,000.
• Duration up to 3 years.
• Total Number of Bio-Tech projects for 2004 23

30
Generic RD and Technology Transfer Support

• Collaborative pre competitive generic
  technologies.
• Grants 66 of approved budget.
• Over 5 participants (IndustryAcademia)
• Examples of consortia Pharmalogica (pharma)
  and Tevel (agriculture).
• New Consortium Cell Therapy and Stem Cell
  derived products.

31
Supporting of Industry Academia Technology
Transfer
NOFAR program Nofar program is dedicated to
Biotechnology. 9 millions NIS Grants were
approved to 28 new project in 2002.
MAGNETON program Technological transfer from
Academia to Industry. 7 million NIS Grants were
approved to 10 new Biotechnological projects in
2002.
32
Israel, Italy and Europe Working together
European Union RD Framework Program managed by
ISrael Europe RD (ISERD) 52 (of 324) Israeli
Groups received FP5 Biotechnology grants at a
total of 11.1M . FP6 Life Science Budget 2,225M
. The Italy-Israel Agreement on Industrial,
Scientific and Technological Research Scientific
Cooperation
33
Biotech Israel 24-26 May 2005www.kenes.com/b
iotech
For further information contactUfficio Affari
EconomiciAmbasciata d'IsraeleVia Michele
Mercati 1400197 Roma, ItalyTel 39 06
36198673-603Fax [phone]Email
econo-assist_at_roma.mfa.gov.ilWebsite
www.roma.mfa.gov.il